Related Experiment Videos
A primer on HIV type 1-specific immune function and REMUNE
R B Moss1, W K Giermakowska, J R Savary
1The Immune Response Corporation, Carlsbad, California 92008, USA.
AIDS Research and Human Retroviruses
|July 22, 1998
Summary
This study explores REMUNE, an immune-based therapy for HIV-1, which may restore immune function lost early in infection. Clinical trials are evaluating its potential for chronic HIV management.
Area of Science:
- Immunology
- Virology
- Therapeutics
Background:
- HIV-1 infection leads to early loss of antigen recognition, impairing immune responses.
- Nonprogressive HIV disease highlights the potential for strong immune responses.
- Highly Active Antiviral Drug Therapy (HAART) is standard care, but may not restore immune function if initiated late.
Purpose of the Study:
- To investigate the effects of REMUNE, an immune-based therapy, on HIV-1-seropositive individuals.
- To assess REMUNE's potential to reconstitute HIV-1-specific immune function.
Main Methods:
- Investigated REMUNE's impact on HIV-1-seropositive individuals.
- Measured immune responses including delayed-type hypersensitivity, lymphocyte proliferation, Th1 cytokine, and beta-chemokine production.
- Ongoing Phase II and Phase III clinical trials involving thousands of participants.
Main Results:
- REMUNE demonstrated stimulation of HIV-1-specific immune function.
- Observed increases in delayed-type hypersensitivity, lymphocyte proliferation, Th1 cytokine, and beta-chemokine production.
Conclusions:
- REMUNE shows promise in stimulating HIV-1-specific immune function.
- Further clinical testing is crucial to determine REMUNE's utility in chronic HIV-1 management.
- Immune-based therapies like REMUNE may offer additional treatment options for HIV-1.